Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.
The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.
Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
No greater risks for upstaging or positive surgical margins were observed among patients who underwent RPN for cT2a tumors over the short term.
Elevated serum levels of BNP and NT-proBNP prior to nephrectomy are associated with an increased likelihood of RCC progression.
1. Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation). 2. This association may reflect incidental detection and over-diagnosis of renal masses, with an increased 
Access to treatment should be considered as important as the research leading to clinical improvements.
Patients who underwent radical nephrectomy had 2-fold greater decline in eGFR decline and 2-fold greater mortality compared with those who had a partial nephrectomy.
Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).
Renal & Urology News spoke with Jonathan Silberstein, MD, about creating surgical models using a 3D printer.
Stereotactic ablative radiotherapy is associated with high 2- and 4-year rates of local cancer control and progression-free and cancer-specific survival.
In a multinational, prospective study, just 5% of cases converted.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Partial nephrectomy was associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma.
Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
Levels of alkaline phosphatase, calcium, and hemoglobin can independently predict bone metastasis in patients with renal cell carcinoma, Chinese investigators report.
At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.
Robotic-assisted radical nephrectomy (RN) is associated with higher hospital costs and prolonged operating time compared with laparoscopic RN.
Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.
40% of cancer diagnoses tied to extra weight; rate higher in older individuals, females.
Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.
In a study, partial nephrectomy was associated with a 66% lower risk for stage 4 or higher CKD versus radical nephrectomy.
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.
Renal and Urology News Articles
- Lymphoceles: A Contemporary Review and an Approach for Prevention
- Anticoagulants Tied With Stroke, Hemorrhage in CKD
- Coronary Artery Calcification Risk Factors in CKD Identified
- Pulmonary Hypertension Linked With Worse Prognosis in CKD, ESRD
- Adverse Prostate Cancer Pathology Accurately Predicted With MRI
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)